Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05776251 · ClinicalTrials.gov registry record · NA

taVNS for Persistent Symptoms From Lyme Disease

A NA study of Post-Treatment Lyme Disease, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT05776251: Recruiting NA study of Post-Treatment Lyme Disease, sponsored by Columbia University.

NCT05776251 is a NA study of Post-Treatment Lyme Disease that is actively recruiting participants, run by Columbia University. The registered enrollment target is 12 participants, below the 56-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05776251, a NA study of Post-Treatment Lyme Disease, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to reduce the burden of multisystem symptoms in patients with PTLS. This study seeks to address an important goal: to assess the safety, feasibility, and tolerability of a new non-invasive, non-pharmacologic treatment for patients with symptoms that persist despite prior antibiotic treatment for Lyme disease.

Primary Outcome

To assess feasibility of conducting a study of taVNS for patients with persistent symptoms after Lyme disease, recruitment will be calculated from the number of participants in the study.

Interventions

  • DEVICE taVNS

Study Locations (1)

New York

  • Lyme and Tick-Borne Diseases Research Center - New York

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-05-08
Est. Completion 2026-08
Phase NA
Columbia University

958 total trials

What NCT05776251 shows while recruiting

NCT05776251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 56-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Post-Treatment Lyme Disease appearing as the primary indexed condition, and to 1 intervention - of which taVNS is the first listed.

NCT05776251 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05776251 about?

NCT05776251 is a clinical study titled "taVNS for Persistent Symptoms From Lyme Disease". This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to ...

What is the current status of trial NCT05776251?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2023-05-08. Estimated completion is 2026-08.

What conditions does trial NCT05776251 study?

This clinical trial studies the following conditions: Post-Treatment Lyme Disease.

What interventions are being tested in trial NCT05776251?

The interventions under investigation include: taVNS (DEVICE).

Who is sponsoring clinical trial NCT05776251?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05776251 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Treatment Lyme Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05776251, the US trial registry maintained by the National Library of Medicine. NCT05776251 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.